Presentación de la ponencia "Eficacia, Efectividad, Eficiencia" por Armando Pérez de Prado en los Diálogos EPIC_Cierre Percutáneo de la Orejuela Izquierda el 15 de Marzo de 2018 en Madrid (España)
Presentación "Análisis de coste efectividad con los nuevos antiagregantes. Causas de infra-utilización en España" del Dr. José Luis Ferreiro durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Manejo de la antiagregación ajustada a las pruebas de reactividad plaquetaria. Experiencia, Resultados y futuro de un programa nacional" del Dr. Daniel Aradi durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Conferencia magistral "20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia y evolución de las redes de infarto" del Dr. Petr Widimsky durante la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Utilidad de las técnicas de imagen de la insuficiencia cardiaca y trasplante ¿Qué técnica debemos utilizar y qué nos aporta en cada situación clínica?
VIERNES, 17 DE JUNIO 10:30-12:15 SALÓN DE ACTOS
Trasplante cardiaco. ¿Es posible la detección no invasiva del rechazo agudo?
José Antonio Vázquez de Prada, Santander
Ponencia presentada por el Dr. Domingo Pascual Figal en el directo online ‘Lo mejor del Congreso Europeo de IC Atenas 2019’, realizado en la Casa del Corazón el 5 de junio de 2019
Presentación "Análisis de coste efectividad con los nuevos antiagregantes. Causas de infra-utilización en España" del Dr. José Luis Ferreiro durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Manejo de la antiagregación ajustada a las pruebas de reactividad plaquetaria. Experiencia, Resultados y futuro de un programa nacional" del Dr. Daniel Aradi durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Conferencia magistral "20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia y evolución de las redes de infarto" del Dr. Petr Widimsky durante la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Utilidad de las técnicas de imagen de la insuficiencia cardiaca y trasplante ¿Qué técnica debemos utilizar y qué nos aporta en cada situación clínica?
VIERNES, 17 DE JUNIO 10:30-12:15 SALÓN DE ACTOS
Trasplante cardiaco. ¿Es posible la detección no invasiva del rechazo agudo?
José Antonio Vázquez de Prada, Santander
Ponencia presentada por el Dr. Domingo Pascual Figal en el directo online ‘Lo mejor del Congreso Europeo de IC Atenas 2019’, realizado en la Casa del Corazón el 5 de junio de 2019
Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...Fundacion EPIC
Presentación de la ponencia "Cierre Percutáneo de Orejuela Izquierda. Evidencia clínica: dónde estamos?" realizada por Raul Moreno en los Diálogos EPIC_Cierre Percutáneo de la Orejuela Izquierda el 15 de Marzo de 2018 en Madrid (España)
Left atrial appendage closure. Clinical evidence; where we are? by Raul Moreno at Diálogos EPIC_Percutaneous left atrial appendage closure, March 15th 2018 in Madrid (Spain)
Stroke prevention services - quality & safety indicatorsHelicon Health
Prof David Patterson, Consultant Cardiologist, Professor of Cardiovascular Medicine and CEO of Helicon Health, gave this presentation at Commissioning Live - November 2014. He covers a range of issues including better identification of patients with atrial fibrillation and better management of anticoagulation patients.
Helicon Health's web-based integrated package - HeliconHeart - is compliant with National Institute for Health and Care Excellence (NICE) guidelines on anticoagulation and self-monitoring, and cited as a learning exemplar in NICE’s guidelines for atrial fibrillation.
Novedades en el manejo del paciente con FA: actualización tras AHA 2016
22/11/2016 19:30h Casa del Corazón, Madrid
http://manejofa.secardiologia.es
#manejoFA
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria percutánea. Guías y preguntas abiertas
Dr. Antonio Fernández Ortiz, Hospital Universitario Clínico San Carlos (Madrid)
Clinical Genomics for Personalized Cancer Medicine: Recent Advances, Challeng...Yoon Sup Choi
I reviewed recent advances, challenges, and opportunities to implement clinical cancer genomics. Case studies of advanced systems, such as Foundation Medicine, MI-ONCOSEQ are introduced for benchmark. A few fundamental limitations to establish personalized oncology are also discussed.
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
¿Qué se recomienda y qué es lo que hacemos?
VIERNES, 17 DE JUNIO 12.45-14.15 SALÓN DE ACTOS
En la prevención y seguimiento de los pacientes en riesgo de cardiotoxicidad
Xavier Bosch Genover, Barcelona
Les comparto la publicación del estudio Xatoa
Nosotros en la Clínica de Mérida participamos como investigadores en el reclutamiento y análisis de datos de los pacientes de nuestra consulta diaria quienes han recibido el beneficio de la Terapia de Inhibición de Doble Vía.
Es un gusto enorme contribuir al desarrollo del conocimiento médico global 🌎
Atrial fibrillation (afib) is one of the main causes of strokes in the US. New treatment options are available - both medical therapy (such as new blood thinners) and procedures (watchman left atrial appendage closure).
Drs. Lorenzen and Escobar’s CMC X-Ray Mastery Project: October CasesSean M. Fox
Drs. Breeanna Lorenzen and Daniel Escobar are Emergency Medicine Residents and interested in medical education. With the guidance of Dr. Michael Gibbs, a notable Professor of Emergency Medicine, they aim to help augment our understanding of emergent imaging. Follow along with the EMGuideWire.com team as they post these educational, self-guided radiology slides. This set will cover:
- Disconnect VP shunt
- PFO Closure Device
- Implanted Baclofen Pump
- Pnuemobilia
- Common Bile Duct Stent
- Dextrocardia
- Implantable Cardioverter Device
- Left Ventricular Assist Device (LVAD)
Fundación EPIC _ Tratamiento anticoagulante/antiagregante al alta en TAVIFundacion EPIC
Presentación de la ponencia "Tratamiento anticoagulante/antiagregante al alta en TAVI" Por el Dr. Ferreiro en los Diálogos EPIC_Retos Clínicos en Válvulas Transcatéter/ Clinical Challenges in TAVR today, el 10 de Mayo de 2018 en Barcelona (España)
Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...Fundacion EPIC
Presentación de la ponencia "Cierre Percutáneo de Orejuela Izquierda. Evidencia clínica: dónde estamos?" realizada por Raul Moreno en los Diálogos EPIC_Cierre Percutáneo de la Orejuela Izquierda el 15 de Marzo de 2018 en Madrid (España)
Left atrial appendage closure. Clinical evidence; where we are? by Raul Moreno at Diálogos EPIC_Percutaneous left atrial appendage closure, March 15th 2018 in Madrid (Spain)
Stroke prevention services - quality & safety indicatorsHelicon Health
Prof David Patterson, Consultant Cardiologist, Professor of Cardiovascular Medicine and CEO of Helicon Health, gave this presentation at Commissioning Live - November 2014. He covers a range of issues including better identification of patients with atrial fibrillation and better management of anticoagulation patients.
Helicon Health's web-based integrated package - HeliconHeart - is compliant with National Institute for Health and Care Excellence (NICE) guidelines on anticoagulation and self-monitoring, and cited as a learning exemplar in NICE’s guidelines for atrial fibrillation.
Novedades en el manejo del paciente con FA: actualización tras AHA 2016
22/11/2016 19:30h Casa del Corazón, Madrid
http://manejofa.secardiologia.es
#manejoFA
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria percutánea. Guías y preguntas abiertas
Dr. Antonio Fernández Ortiz, Hospital Universitario Clínico San Carlos (Madrid)
Clinical Genomics for Personalized Cancer Medicine: Recent Advances, Challeng...Yoon Sup Choi
I reviewed recent advances, challenges, and opportunities to implement clinical cancer genomics. Case studies of advanced systems, such as Foundation Medicine, MI-ONCOSEQ are introduced for benchmark. A few fundamental limitations to establish personalized oncology are also discussed.
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
¿Qué se recomienda y qué es lo que hacemos?
VIERNES, 17 DE JUNIO 12.45-14.15 SALÓN DE ACTOS
En la prevención y seguimiento de los pacientes en riesgo de cardiotoxicidad
Xavier Bosch Genover, Barcelona
Les comparto la publicación del estudio Xatoa
Nosotros en la Clínica de Mérida participamos como investigadores en el reclutamiento y análisis de datos de los pacientes de nuestra consulta diaria quienes han recibido el beneficio de la Terapia de Inhibición de Doble Vía.
Es un gusto enorme contribuir al desarrollo del conocimiento médico global 🌎
Atrial fibrillation (afib) is one of the main causes of strokes in the US. New treatment options are available - both medical therapy (such as new blood thinners) and procedures (watchman left atrial appendage closure).
Drs. Lorenzen and Escobar’s CMC X-Ray Mastery Project: October CasesSean M. Fox
Drs. Breeanna Lorenzen and Daniel Escobar are Emergency Medicine Residents and interested in medical education. With the guidance of Dr. Michael Gibbs, a notable Professor of Emergency Medicine, they aim to help augment our understanding of emergent imaging. Follow along with the EMGuideWire.com team as they post these educational, self-guided radiology slides. This set will cover:
- Disconnect VP shunt
- PFO Closure Device
- Implanted Baclofen Pump
- Pnuemobilia
- Common Bile Duct Stent
- Dextrocardia
- Implantable Cardioverter Device
- Left Ventricular Assist Device (LVAD)
Fundación EPIC _ Tratamiento anticoagulante/antiagregante al alta en TAVIFundacion EPIC
Presentación de la ponencia "Tratamiento anticoagulante/antiagregante al alta en TAVI" Por el Dr. Ferreiro en los Diálogos EPIC_Retos Clínicos en Válvulas Transcatéter/ Clinical Challenges in TAVR today, el 10 de Mayo de 2018 en Barcelona (España)
Estado actual del cierre de orejuela, por Juan Miguel Ruiz NodarFundacion EPIC
Presentación del caso "Estado actual del cierre de orejuela", por Juan Miguel Ruiz Nodar en el webinar Epic Learning Focus On Fast Track en Cierre de Orejuela Izquierda el 30 de marzo de 2021.
Fast Track en Cierre de Orejuela. Herramientas para facilitar el procedimient...Fundacion EPIC
Presentación del caso "Fast Track en Cierre de Orejuela. Herramientas para facilitar el procedimiento", por Ignacio Cruz González en el webinar Epic Learning Focus On Fast Track en Cierre de Orejuela Izquierda el 30 de marzo de 2021.
Cierre Orejuela con dispositivo Watchman FLX, por Dabit ArzamendiFundacion EPIC
Presentación del caso "Cierre Orejuela con dispositivo Watchman FLX" por Dabit Arzamendi en el webinar Epic Learning Focus On Fast Track en Cierre de Orejuela Izquierda el 30 de marzo de 2021.
Nuevas tecnicas intervencionistas en el manejo de la HTP, Dr Federico Gutierr...Fundacion EPIC
Presentación de "Nuevas tecnicas intervencionistas en el manejo de la HTP" por el Dr Federico Gutierrez-Larraya del Hospital Universitario La Paz, en el I Curso IVP, Intervencionismo Vascular Pulmonar, organizado por EpicLearning (Fundación EPIC) el 23 de marzo de 2021.
High risk pulmonary embolism , Dr David JimenezFundacion EPIC
Presentación de "High risk pulmonary embolism" por el Dr David Jimenez del Hospital Ramón y Cajal, en el I Curso IVP, Intervencionismo Vascular Pulmonar, organizado por EpicLearning (Fundación EPIC) el 23 de marzo de 2021.
Estenosis de venas pulmonares: causas y manejo, Dr Carlos AlvarezFundacion EPIC
Presentación de "Estenosis de venas pulmonares: causas y manejo" por el Dr Carlos Alvarez del Hospital Universitario La Paz, en el I Curso IVP, Intervencionismo Vascular Pulmonar, organizado por EpicLearning (Fundación EPIC) el 23 de marzo de 2021.
Angioplastia pulmonar en hipertension pulmonar tromboembolica cronica por la ...Fundacion EPIC
Presentación de "Angioplastia pulmonar en hipertension pulmonar tromboembolica cronica por la Dra Maite Velazquez del Hospital Universitario 12 de Octubre, en el I Curso IVP, Intervencionismo Vascular Pulmonar, organizado por EpicLearning (Fundación EPIC) el 23 de marzo de 2021.
Tratamiento intervencionista: ¿una alternativa real a la fibrinolisis sistemi...Fundacion EPIC
Presentación de "Tratamiento intervencionista: ¿una alternativa real a la fibrinolisis sistemica? por Dr Ignacio Amat del Hospital Universitario de Valladolid, en el I Curso IVP, Intervencionismo Vascular Pulmonar, organizado por EpicLearning (Fundación EPIC) el 23 de marzo de 2021.
Patologia de las arterias pulmonares en cardiopatias congenitas ,por Jose Lui...Fundacion EPIC
Presentación de "Patologia de las arterias pulmonares en cardiopatias congenitas" por Jose Luis Zunzunegui del Hospital Gregorio Marañon, en el I Curso IVP, Intervencionismo Vascular Pulmonar, organizado por EpicLearning (Fundación EPIC) el 23 de marzo de 2021.
Novedades en el diagnostico y tratamiento medico de la Hipertension Pulmonar,...Fundacion EPIC
Presentación de "Novedades en el diagnostico y tratamiento medico de la Hipertension Pulmonar" por la Dra Clara Soto del Hospital Universitario La Paz, en el I Curso IVP, Intervencionismo Vascular Pulmonar, organizado por EpicLearning (Fundación EPIC) el 23 de marzo de 2021.
Presentación de "Válvula Aórtica Bicúspide" por el Dr. Ramiro Trillo en el webinar Diálogos en la Red "Fronteras de la TAVI: Cuando la experiencia complementa a la evidencia". Organizado por EpicLearning
Presentación de "Paciente Polivalvular" por la Dra Soledad Ojeda en el webinar Diálogos en la Red "Fronteras de la TAVI: Cuando la experiencia complementa a la evidencia". Organizado por EpicLearning
Presentación de "Procedimiento Valve-in-Valve" por el Dr. Bruno García en el webinar Diálogos en la Red "Fronteras de la TAVI: Cuando la experiencia complementa a la evidencia". Organizado por EpicLearning
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
18. Situación local: CI a ACO
Cruz González et al. Poster presented at ISPOR 2015
19. Ejemplo local: 10% FAnv = LAAC
Spain
495.998
1,5%
70,0%
yes
70,0%
CHADS2of2orhigher
57,0%
All
100,0%
2.078
60%
40%
0%
40%
20%
40%
10%
35%
15%
40%
SelectCountry
Population
%CHADS2of2orhigher
Percent of AF patients less than 85 years old
Consider only patients less than 85 years old?
Prevalence of Atrial Fibrillation
% of AF that is Nonvalvular AF
CHADS2scoretoconsider
TherapySelection
% getting Warfarin
CurrentTherapyStrategy
Total eligible patients
Warfarin status to consider?
% of warfarin patients to consider
% getting No Therapy/Aspirin
FutureTherapyStrategywithpharmaceuticals&WATCHMAN®
Inputsabovemusttotal100%
Inputs above most total 100%
FutureTherapyStrategywithpharmaceuticalsonly
% getting new OAC
Inputs above must total 100%
% getting Warfarin
% getting Warfarin
% getting new OAC
% getting new OAC
%gettingWATCHMAN®Device
% getting No Therapy/Aspirin
% getting No Therapy/Aspirin
5 años 10 años
21. Ejemplo local: CI / intolerancia a ACO
Spain
495.998
1,5%
70,0%
yes
70,0%
CHADS2of2orhigher
57,0%
Contraindicated & Intolerant
40,0%
831Total eligible patients
Warfarin status to consider?
% of AF patients Contraindicated & Intolerant to warfarin
SelectCountry
Population
%CHADS2of2orhigher
Percent of AF patients less than 85 years old
Consider only patients less than 85 years old?
Prevalence of Atrial Fibrillation
% of AF that is Nonvalvular AF
CHADS2scoretoconsider
10%
90%
Inputs above must total 100%
% getting Warfarin
% getting new OAC
%gettingWATCHMAN®Device
% getting No Therapy/Aspirin
FutureTherapyStrategywithpharmaceuticals&WATCHMAN®
5 años 10 años
23. Perspectiva
Asistencia ventricular como terapia de destino iPCSK9 en HCF HTZ / Enf. aterosclerótica
Kazi et al. JAMA. 2016;316:743Baras et al. JACC: Heart Failure Jan 2017, 555; DOI: 10.1016/j.jchf.2016.09.008
24. Perspectiva
Asistencia ventricular como terapia de destino iPCSK9 en HCF HTZ / Enf. aterosclerótica
ICER / QALY > 200.000$ ICER / QALY > 400.000$
Kazi et al. JAMA. 2016;316:743Baras et al. JACC: Heart Failure Jan 2017, 555; DOI: 10.1016/j.jchf.2016.09.008
25. ¿Qué más necesitamos? Mejor evidencia
• Evaluation of WATCHMAN Left Atrial Appendage
Occlusion Device in Patients With Atrial Fibrillation Versus
Rivaroxaban (NCT02549963)
• PRAGUE-17: Left Atrial Appendage Closure vs. Novel
Anticoagulation Agents in Atrial Fibrillation
(NCT02426944)
• A Pilot Study of Edoxaban in Patients With Non-Valvular
Atrial Fibrillation and Left Atrial Appendage Closure
(NCT03088072)
• Safety and Efficacy of Left Atrial Appendage Closure
Versus Antithrombotic Therapy in Patients With Atrial
Fibrillation Undergoing Drug-Eluting Stent Implantation
Due to Complex Coronary Artery Disease (NCT02606552)
• Prevention of Stroke by Left Atrial Appendage Closure in
Atrial Fibrillation Patients After Intracerebral Hemorrhage
(NCT02830152).
Pérez de Prado et al. Rev Esp Cardiol 2018; doi: 10.1016/j.rec.2017.10.044